Protocol for a phase III randomised trial of image-guided intensity modulated radiotherapy (IG-IMRT) and conventional radiotherapy for late small bowel toxicity reduction after postoperative adjuvant radiation in Ca cervix
Supriya Chopra, Reena Engineer, Umesh Mahantshetty, Shagun Misra, Reena Phurailatpam, Siji N Paul, Sadhna Kannan, Rajendra Kerkar, Amita Maheshwari, Ts Shylasree, Jaya Ghosh, Sudeep Gupta, Biji Thomas, Shalini Singh, Sanjiv Sharma, Srinivas Chilikuri, Shyam Kishore Shrivastava, Supriya Chopra, Reena Engineer, Umesh Mahantshetty, Shagun Misra, Reena Phurailatpam, Siji N Paul, Sadhna Kannan, Rajendra Kerkar, Amita Maheshwari, Ts Shylasree, Jaya Ghosh, Sudeep Gupta, Biji Thomas, Shalini Singh, Sanjiv Sharma, Srinivas Chilikuri, Shyam Kishore Shrivastava
Abstract
Introduction: External beam radiation followed by vaginal brachytherapy (±chemotherapy) leads to reduction in the risk of local recurrence and improves progression-free survival in patients with adverse risk factors following Wertheim's hysterectomy albeit at the risk of late bowel toxicity. Intensity Modulated Radiotherapy (IMRT) results in reduction in bowel doses and has potential to reduce late morbidity, however, needs to be confirmed prospectively in a randomised trial. The present randomised trial tests reduction if any in late small bowel toxicity with the use of IMRT in postoperative setting.
Methods and analysis: Patients more than 18 years of age who need adjuvant (chemo) radiation will be eligible. Patients with residual pelvic or para-aortic nodal disease, history of multiple abdominal surgeries or any other medical bowel condition will be excluded. The trial will randomise patients into standard radiation or IMRT. The primary aim is to compare differences in late grades II-IV bowel toxicity between the two arms. The secondary aims of the study focus on evaluating correlation of dose-volume parameters and late toxicity and quality of life. The trial is planned as a multicentre randomised study. The trial is designed to detect a 13% difference in late grades II-IV bowel toxicity with an α of 0.05 and β of 0.80. A total of 240 patients will be required to demonstrate the aforesaid difference.
Ethics and dissemination: The trial is approved by institutional ethics review board and will be routinely monitored as per standard guidelines. The study results will be disseminated via peer reviewed scientific journals, conference presentations and submission to regulatory authorities.
Registration: The trial is registered with clinicaltrials.gov (NCT 01279135).
References
- Rotman M, Sedlis A, Piedmonte MR, et al. A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J of Radiat Oncol Biol and Phys 2006;65:169–76
- Peters WA, III, Liu PY, Barrett RJ, IIet al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000;18:1606–13
- Sedlis A, Bundy BN, Rotman MZ, et al. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage ib carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a gynecologic oncology group study. Gynecol Oncol 1999;73:177–83
- Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:744–51
- Chen S-W, Liang JA, Yang SN, et al. Radiation injury to intestine following hysterectomy and adjuvant radiotherapy for cervical cancer. Gynecol Oncol 2004;95:208–14
- Frykholm GJ, Glimelius B, Pahlman L. Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects. Dis Colon Rectum 1993;36:564–72
- Kavanagh BD, Pan CC, Dawson LA, et al. Radiation dose volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys 2010;76:S101–7
- Baglan KL, Frazier RC, Yan D, et al. The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys 2002;52:176–83
- Robertson JM, Lockman D, Yan D, et al. The dose volume relationship of small bowel irradiation and acute grade III diarrhoea during radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 2007;69:732–9
- Letschert JG, Lebesque JV, deBoer RW, et al. Dose-volume correlation in radiation-related late small-bowel complications: a clinical study. Radiother Oncol 1990;18:307–20
- Mundt AJ, Roeske JC. Can intensity-modulated radiation therapy replace brachytherapy in the management of cervical cancer? Counterpoint. Brachytherapy 2002;1:192–4
- Portelance L, Winter K, Jhingran A, et al. Post-operative pelvic intensity modulated radiation therapy (IMRT) with chemotherapy for patients with cervical carcinoma/RTOG 0418 phase II study. Int J Radiat Oncol Biol Phys 2009;75:S640–1
- Schwarz JK, Wahab S, Grigsby PW. Prospective phase I/II trial of helical tomotherapy with or without chemotherapy for postoperative cervical cancer patients. Int J Radiat Oncol Biol Phys 2009;81:1258–63
- Kabarriti R, Thawani N, Gao W, et al. Feasibility and acute toxicity of intensity modulated radiation therapy with CDDP chemotherapy for postoperative pelvic radiation in patients with cervical cancer. Int J Radiat Oncol Biol Phys 2009;75:S376–7
- Vandecasteele K, Tummers P, Makar A, et al. Postoperative intensity modulated arc therapy for cervical and endometrial cancers: a prospective report on toxicity. Int J Radiat Oncol Biol Phys 2012;84:408–14.
Source: PubMed